ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2(−/−) ovarian cancer cells

Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum. However, the acquired resistance...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mol Cancer Ther
Main Authors: Liu, Lu, Cai, Shurui, Han, Chunhua, Banerjee, Ananya, Wu, Dayong, Cui, Tiantian, Xie, Guozhen, Zhang, Junran, Zhang, Xiaoli, McLaughlin, Eric, Yin, Ming, Backes, Floor J., Chakravarti, Arnab, Zheng, Yanfang, Wang, Qi-En
格式: Artigo
語言:Inglês
出版: 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6946874/
https://ncbi.nlm.nih.gov/pubmed/31534014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0242
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍